Latest Insider Transactions at Arcus Biosciences, Inc. (RCUS)
This section provides a real-time view of insider transactions for Arcus Biosciences, Inc. (RCUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arcus Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arcus Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2024
|
Dimitry Sa Nuyten Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,385
-5.37%
|
$91,545
$17.95 P/Share
|
|
Sep 15
2024
|
Jennifer Jarrett Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,670
-6.24%
|
$215,390
$17.95 P/Share
|
|
Aug 13
2024
|
Alexander Azoy Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,357
-6.64%
|
$18,998
$14.97 P/Share
|
|
Jun 15
2024
|
Carolyn C. Tang General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,182
-3.62%
|
$66,912
$16.97 P/Share
|
|
Jun 15
2024
|
Jennifer Jarrett Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,670
-5.87%
|
$202,720
$16.97 P/Share
|
|
Jun 15
2024
|
Juan C. Jaen President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,969
-2.04%
|
$111,504
$16.97 P/Share
|
|
Jun 15
2024
|
Terry J Rosen Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,670
-0.32%
|
$202,720
$16.97 P/Share
|
|
Jun 06
2024
|
Nicole Lambert Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+25.93%
|
-
|
|
Jun 06
2024
|
Antoni Ribas Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+21.68%
|
-
|
|
Jun 06
2024
|
Andrew J Perlman Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+22.27%
|
-
|
|
Jun 06
2024
|
Patrick Machado Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+24.93%
|
-
|
|
Jun 06
2024
|
Kathryn E Falberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+13.19%
|
-
|
|
Jun 06
2024
|
David L. Lacey Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+12.72%
|
-
|
|
Jun 06
2024
|
Yasunori Kaneko Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+35.59%
|
-
|
|
Mar 27
2024
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
11,551
-5.09%
|
$196,367
$17.55 P/Share
|
|
Mar 18
2024
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
13,449
-2.81%
|
$242,082
$18.23 P/Share
|
|
Feb 27
2024
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Indirect |
23,132
-1.91%
|
$462,640
$20.1 P/Share
|
|
Feb 27
2024
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
34,070
-12.42%
|
$681,400
$20.11 P/Share
|
|
Feb 26
2024
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Indirect |
3,900
-0.32%
|
$78,000
$20.06 P/Share
|
|
Feb 26
2024
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
24,555
-8.22%
|
$491,100
$20.07 P/Share
|
|
Jan 29
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
15,238,095
+33.64%
|
$319,999,995
$21.0 P/Share
|
|
Jan 23
2024
|
Carolyn C. Tang General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
26,700
+18.9%
|
-
|
|
Jan 23
2024
|
Alexander Azoy Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,850
+31.7%
|
-
|
|
Jan 23
2024
|
Juan C. Jaen President |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+10.49%
|
-
|
|
Jan 23
2024
|
Ii Robert C. Goeltz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,300
+22.56%
|
-
|
|
Jan 23
2024
|
Dimitry Sa Nuyten Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+22.01%
|
-
|
|
Jan 23
2024
|
Jennifer Jarrett Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+11.8%
|
-
|
|
Jan 23
2024
|
Terry J Rosen Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+2.46%
|
-
|
|
Jan 02
2024
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Indirect |
6,975
-0.57%
|
$139,500
$20.09 P/Share
|
|
Jan 02
2024
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,004
-3.72%
|
$40,080
$20.0 P/Share
|
|
Dec 29
2023
|
Terry J Rosen Chief Executive Officer |
BUY
Acquisition or disposition by will or laws
|
Direct |
448
+0.01%
|
-
|
|
Dec 22
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
21,521
-7.68%
|
$365,857
$17.76 P/Share
|
|
Dec 20
2023
|
Alexander Azoy Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
68
-0.66%
|
$1,224
$18.21 P/Share
|
|
Dec 19
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,492
-3.94%
|
$206,856
$18.09 P/Share
|
|
Dec 19
2023
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,808
-4.96%
|
$50,544
$18.09 P/Share
|
|
Dec 19
2023
|
Alexander Azoy Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
661
-6.04%
|
$11,898
$18.09 P/Share
|
|
Dec 19
2023
|
Dimitry Sa Nuyten Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,540
-2.12%
|
$27,720
$18.09 P/Share
|
|
Dec 19
2023
|
Carolyn C. Tang General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,076
-4.43%
|
$73,368
$18.09 P/Share
|
|
Dec 19
2023
|
Terry J Rosen Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,000
-0.36%
|
$252,000
$18.09 P/Share
|
|
Dec 19
2023
|
Juan C. Jaen President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,259
-2.03%
|
$112,662
$18.09 P/Share
|
|
Dec 18
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,250
-3.71%
|
$191,250
$17.74 P/Share
|
|
Dec 18
2023
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,749
-4.63%
|
$46,733
$17.74 P/Share
|
|
Dec 18
2023
|
Alexander Azoy Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
647
-5.58%
|
$10,999
$17.74 P/Share
|
|
Dec 18
2023
|
Dimitry Sa Nuyten Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,507
-2.03%
|
$25,619
$17.74 P/Share
|
|
Dec 18
2023
|
Carolyn C. Tang General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,991
-4.16%
|
$67,847
$17.74 P/Share
|
|
Dec 18
2023
|
Terry J Rosen Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,705
-0.35%
|
$232,985
$17.74 P/Share
|
|
Dec 18
2023
|
Juan C. Jaen President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,128
-1.95%
|
$104,176
$17.74 P/Share
|
|
Dec 01
2023
|
Alexander Azoy Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
282
-2.37%
|
$3,948
$14.95 P/Share
|
|
Sep 22
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
21,369
-6.59%
|
$406,011
$19.99 P/Share
|
|
Sep 18
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,506
-3.72%
|
$250,120
$20.4 P/Share
|